Independent drugmaker Servier has signed a deal with fellow French firm ILTOO Pharma in a partnership prioritizing the development of a treatment for lupus.
The companies have announced the signature of an exclusive license option agreement for the development and commercialization of the ILT-101 drug candidate (low-dose interleukin-2) for the treatment of autoimmune diseases, with systemic lupus erythematosus (SLE) as the first target indication.
"The approach taken by ILTOO Pharma’s team persuaded us of ILT-101’s potential to treat highly debilitating diseases, for which no effective treatment exists today"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze